Clinical Trial

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The investigators propose to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA treatment in patients with bone metastases from breast cancer and castration-resistant prostate cancer
Protocol Amendment History 1 change
minor Completion pushed: 2026-06 -> 2026-09 2026-07-22
Trial Details
NCT Number NCT04549207
Lead Sponsor Ottawa Hospital Research Institute
Conditions Breast Cancer, Castration-resistant Prostate Cancer
Enrollment 240 participants
Start Date 2020-10-09
Primary Completion 2025-04-17 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-21